G-CSF Mobilized Leukopaks
StemExpress introduces G-CSF Mobilized Leukopaks to their extensive collection of blood-derived cell products. After two years of working with their clients to develop a protocol in which institute protocol standards were evaluated, a mobilized Leukopak procedure was developed to bring a high-quality product to clients demanding low granulocyte contamination, high cell viability, and an increase in CD34+ cell frequencies.
According to Joe Anderson, Ph.D., Assistant Professor of Internal Medicine at UC Davis, “we worked closely with StemExpress to obtain a product that had a low granulocyte and low hematocrit population among the mononuclear cells. The final protocol for obtaining a high-quality mobilized leukopak exceeded our expectations. Not only did we receive an exceptional product but we have received all mobilized Leukopaks from StemExpress within two weeks from the time of order.”
Representative flow panel of fresh G-CSF mobilized leukopak. Enriched MNC population with low granulocytes (20.76%), high viability (97.65%), and high percentage of CD34+ cells (1.68%).
Human mobilized Leukopaks provides a large number of mononuclear cells (MNCs) that contains a rich source of hematopoietic stem cells as compared to traditional Leukopaks. This allows researchers greater reproducibility of experiments from a single donor (minimize donor-to-donor variation), increase in scalability of experiments from a single product, and a decrease in same cell variability by obtaining high yields of specific cell types.
Human mobilized peripheral blood Leukopaks are collected from healthy IRB consented donors that are negative for HIV, HBV, and HCV from one of StemExpress’ Stem Cell Collection Centers. Mobilized peripheral blood donors are injected with Granulocyte-Colony Stimulating Factor (G-CSF), which stimulates the bone marrow to produce hematopoietic stem cells and mobilizes them into the bloodstream, over a period of 3–5 days. Mobilized mononuclear cells are collected by a trained technician using the Spectra Optia® Apheresis System one and two days post-injection (1 bag collected per day).
StemExpress’ donation centers adhere to Good Clinical Practice guidelines with IRB approved informed consents and protocols providing the utmost care for their donors and the highest quality of product to their customers. Each donation center employs a staff of certified apheresis technicians and licensed medical physicians to ensure the care and well-being of their donors. Donors undergo a thorough review of their historical and current medical history as well as infectious disease screening every 90-days by a CLIA-certified laboratory.
StemExpress is a life-science company dedicated to advancing science. The company supports biomedical researchers globally by offering human hematopoietic stem cells and blood-derived cell products from bone marrow, cord blood, peripheral blood and mobilized peripheral blood. StemExpress guarantees every sample delivers only the highest purity, viability, and quality investigators need to achieve the best results.